Zhiqiang M. Song
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024-2025 National Multicenter Cross-Sectional Study.
Journal: Helicobacter
Published: April 22, 2026
Comparing potassium-competitive acid blocker-based therapies for Helicobacter pylori infection: A Bayesian network meta-analysis of 77 randomised controlled trials.
Journal: Frontiers in physiology
Published: March 31, 2026
A Self-Adaptive Programming Strategy Enables Local Microenvironment Modulation and Temporal Immunomodulation for Diabetic Infected Bone Regeneration.
Journal: Advanced healthcare materials
Published: January 05, 2026
MSC-mimicking nanovesicle embedded bio-adhesive hydrogel for dual immunomodulation and osteogenesis to promote maxillofacial bone regeneration.
Journal: Bioactive materials
Published: December 13, 2025
Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial.
Journal: Helicobacter
Published: September 19, 2025
Ten-Day Versus 14-Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
Journal: Helicobacter
Published: July 13, 2025
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.
Journal: The Lancet. Infectious diseases
Published: June 13, 2025
Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.
Journal: Chinese medical journal
Published: March 28, 2025
Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial.
Journal: Helicobacter
Published: March 27, 2025
Persistent health inequality in the global burden of digestive diseases attributable to risk factors: a systematic analysis for the Global Burden of Disease Study 2021.
Journal: BMJ public health
Published: February 18, 2025
Comparative analysis of the detection of antibiotic genotypic resistance with gastric mucosa, gastric fluid, and fecal samples in patients with Helicobacter pylori infection.
Journal: Journal of clinical microbiology
Published: December 16, 2024
Last Updated: 09/26/2026